Emanuele Zucca

43PUBLICATIONS
253CO-AUTHORS
Rheumatology and arthritisPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Aug 31, 2026
SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

|Jun 17, 2026
Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

|Jun 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

|May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

|Sep 12, 2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Emanuele Zucca, Luca Ceriani, Giovannino Ciccone

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

Pageof 8

Frequent Collaborators

12 joint publications

Luca Ceriani

11 joint publications

Luciano Cascione

11 joint publications

Francesco Bertoni

7 joint publications

Chiara Tarantelli